A therapeutic solution aimed at slowing and possibly reversing the progression of Myopia (short-sightedness) is on the path from patent to product with the support of a $20,000 grant from Newcastle Innovation.
Dr Sally McFadden from the School of Psychology has been awarded the 2015 Newcastle Innovation Commercialisation in Research Grant at the recent HMRI Awards.
A research discovery identifying novel retinal signals and pathways in the eye causing ocular expansion and Myopia led to the re-purposing of a drug as a new therapeutic target to control myopic eye growth.
Myopia affects more than 1.5 billion people worldwide, with its prevalence on the rise most dramatically in Asia. Currently, there are no proven lasting ways to treat the condition either in terms of stabilising or preventing its progression.
The target drug has a well-established safety and efficacy profile and animal model studies have already shown it can be re-formulated into an ophthalmic drug delivery system that is: easily administered, targeted and cost-effective. Details of test results can be accessed here.
The commercialisation grant will enable Dr McFadden to undertake direct comparative data of therapeutic efficacy and toxicity with other potential anti-myopia drugs. This will enable Newcastle Innovation to engage in more detailed conversations with potential R&D partners with a view to seeking a license to commercially develop the new therapeutic solution to treat myopia.
A patent covering the methods of treatment of compositions of the potential novel formulations has been filed.